治疗前动态增强超声定量分析评估结直肠癌肝转移对化疗联合靶向治疗反应的双中心研究
该双中心回顾性研究纳入中山医院50例结直肠癌肝转移患者为训练队列、上海第十人民医院14例为测试队列,于化疗联合靶向治疗前行动态增强超声定量灌注分析。逻辑回归确定峰值增强和达峰时间为独立预测因素,模型预测治疗反应的AUC在训练队列为0.923、测试队列为0.854。
要点
- 治疗前CEUS定量参数峰值增强(OR=1.640)和达峰时间(OR=0.495)为治疗反应的独立预测因素。
- 基于峰值增强和达峰时间的逻辑回归模型预测效能AUC训练队列0.923、测试队列0.854。
- 峰值增强和达峰时间不受超声仪器和造影剂剂量影响(P>0.05)。
核心结论
- 动态定量灌注分析的CEUS具有高一致性,在预测结直肠癌肝转移对化疗联合靶向治疗反应方面有潜在实用价值。
研究设计与样本
- 双中心回顾性研究,训练队列为复旦大学附属中山医院50例结直肠癌肝转移患者,测试队列为上海市第十人民医院14例患者;治疗前接受CEUS检查,采用VueBox®软件行时间-强度曲线定量灌注分析;以治疗前CT及治疗后3个月随访CT按RECIST 1.1标准判定治疗反应。
诊断标准与关键数值
- 峰值增强OR=1.640(95%CI 1.022-2.633)、达峰时间OR=0.495(95%CI 0.246-0.996)为独立预测因素;逻辑回归模型AUC训练队列0.923、测试队列0.854;峰值增强和达峰时间不受超声仪器和造影剂剂量影响(P>0.05)。
临床应用与阅片要点
- 作者认为,采用动态定量灌注分析的CEUS具有高一致性,在预测结直肠癌肝转移对化疗联合靶向治疗反应方面有潜在实用价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the clinical value of pre-treatment quantitative contrast-enhanced ultrasound (CEUS) in assessing the response of colorectal liver metastases (CRLM) to chemotherapy plus targeted therapy.
METHODS: This study retrospectively enrolled 50 CRLM patients from the Zhongshan Hospital, Fudan University as the training cohort and 14 patients from Shanghai Tenth People's Hospital as the testing cohort. Patients underwent the CEUS examination before receiving chemotherapy (CAPOX, FOLFOX, FOLFIRI, or FOLFOXIRI) plus targeted therapy (Bevacizumab or Cetuximab). The therapy response was determined according to Response Evaluation Criteria in Solid Tumors version 1.1 based on pre-treatment CT and 3-month follow-up CT after therapy. Dynamic analysis was performed by VueBox® software. Time-intensity curves with quantitative perfusion parameters were obtained. In the training cohort, univariable and multivariable logistic regression analyses were used to develop the predictive model of therapy response. The predictive performance of the developed model was validated in the testing cohort.
RESULTS: After the logistic regression analyses, the peak enhancement (PE) (odds ratio = 1.640; 95% confidence intervals [CI] 1.022-2.633) and time to peak (TTP) (odds ratio = 0.495; 95% CI 0.246-0.996) were determined as independent predictive factors. PE and TTP generated from VueBox® were not affected by ultrasound instruments and contrast agent dosage in therapy response evaluation (P > 0.05). The logistic regression model achieved satisfactory prediction performance (area under the curve: 0.923 in the training cohort and 0.854 in the testing cohort).
CONCLUSION: CEUS with dynamic quantitative perfusion analysis, which presents high consistency, has potential practical value in predicting the response of CRLM to chemotherapy plus targeted therapy.
引用
- Zhou BY, Liu H, Pu YY, et al. Quantitative analysis of pre-treatment dynamic contrast-enhanced ultrasound for assessing the response of colorectal liver metastases to chemotherapy plus targeted therapy: a dual-institutional study. Abdom Radiol (NY). 2023. PMID: 37853236. doi:10.1007/s00261-023-04055-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。